Regeneron Pharmaceuticals (REGN) executive details insider stock move

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. reported an insider stock transaction by executive Daniel P. Van Plew, EVP & General Mgr, Industrial.

On 12/09/2025, he reported a transaction coded F involving the disposition of 2,552 shares of common stock at $701.51 per share. After this, he reported beneficial ownership of 21,673 shares held directly, 12,376 shares held indirectly through a 2025 GRAT, and 1,129 shares held through a 401(k) plan.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Van Plew Daniel P

Role EVP & General Mgr, Industrial

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,552	$701.51	$1.79M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 21,673 shares (Direct); Common Stock — 12,376 shares (Indirect, By 2025 GRAT)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Plew Daniel P

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & General Mgr, Industrial

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		F		2,552	D	$701.51	21,673	D
Common Stock								12,376	I	By 2025 GRAT
Common Stock								1,129	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Daniel P. Van Plew	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Regeneron (REGN) disclose in this Form 4?

The filing reports that executive Daniel P. Van Plew had a transaction coded F on 12/09/2025 involving the disposition of 2,552 shares of Regeneron common stock at $701.51 per share.

Who is the Regeneron executive involved in this Form 4 filing?

The reporting person is Daniel P. Van Plew, who serves as EVP & General Mgr, Industrial at Regeneron Pharmaceuticals, Inc.

How many Regeneron shares does the executive hold directly after the transaction?

Following the reported transaction, Daniel P. Van Plew reported beneficial ownership of 21,673 Regeneron common shares held directly.

What indirect Regeneron share ownership does the executive report?

He reports indirect ownership of 12,376 shares held by a 2025 GRAT and 1,129 shares held through a 401(k) Plan.

What type of SEC filing is this for Regeneron (REGN)?

This is a Form 4 filed under Section 16, reporting changes in the beneficial ownership of Regeneron Pharmaceuticals, Inc. equity securities by an executive officer.